Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
AR

NASDAQ · ARTL

Artelo Biosciences, Inc.

Healthcare · Biotechnology

$5.43

Down-$0.20 (-3.55%)

Updated Sep 12, 2026, 8:58 AM

SID Score

6.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.75M
P/E ratio
-0.1
Dividend yield
0.00%
52-week range
$0.66 – $19.91
Volume
41.93K
Avg. volume
491.32K

Price performance

ARTL price history

1M range · 20 trading sessions · Daily adjusted prices

ARTL closed at $5.43 after 20 trading sessions, up 587.17% for the selected period.

Last close
$5.43
Period change
+587.17%
Period low
$0.69
Period high
$6.52
Daily close
View OHLC price history
ARTL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$5.69$5.84$5.35$5.4341.93K
Sep 10, 2026$5.89$6.00$5.6101$5.6343.51K
Sep 9, 2026$6.4147$6.4147$5.98$5.9829.28K
Sep 8, 2026$6.135$6.38$5.918$6.1910.86K
Sep 4, 2026$6.25$6.345$5.92$6.0427.76K
Sep 3, 2026$6.60$6.805$6.22$6.2227.79K
Sep 2, 2026$6.10$6.7057$5.9911$6.5243.16K
Sep 1, 2026$6.05$6.3899$5.70$6.15585.71K
Aug 31, 2026$5.95$6.7899$5.34$6.36591.49K
Aug 28, 2026$5.9301$6.1182$5.5656$5.9643266.71K
Aug 27, 2026$6.1038$6.282$4.68$5.94993.17K
Aug 26, 2026$6.3454$6.57$6.3454$6.395410.28K
Aug 25, 2026$6.30$6.462$6.12$6.454815.91K
Aug 24, 2026$0.6789$0.7098$0.66$0.689105.87K
Aug 21, 2026$0.72$0.73$0.6803$0.692108.9K
Aug 20, 2026$0.7155$0.75$0.7001$0.7124350.68K
Aug 19, 2026$0.7155$0.7499$0.7072$0.72200.52K
Aug 18, 2026$0.702$0.76$0.702$0.7299479.45K
Aug 17, 2026$0.7881$0.7999$0.6902$0.7216.55M
Aug 14, 2026$0.773$0.91$0.7635$0.7902460.51K

Latest ARTL news

The latest Smart Investors Daily articles mentioning ARTL.

Stock researchCompany · Overview

ARTL research

Overview

Company profile and research snapshot.

Company profile

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ARTL recent ratings
DateFirmRatingTarget
Nov 19, 2025Maxim GroupHold—
Sep 8, 2025D. Boral CapitalHold—
Aug 26, 2025D. Boral CapitalBuy—
Aug 18, 2025D. Boral CapitalBuy—
Aug 6, 2025D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

SOLANA BEACH, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that Gregory D. Gorgas, CEO of Artelo Biosciences, will be participating in the H.C. Wainwright 28th Annual Global Investment Conference being held September 14-16, 2026

Yahoo · Aug 27, 2026

Artelo Biosciences Announces Reverse Stock Split

Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026SOLANA BEACH, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced a 1-for-9 reverse stock split (“Reverse Split”) of the Company’s common stock (“Common Stock

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By